Laboratorios Salvat strengthens its commitment to those affected by glaucoma by meeting their specific needs

  • The pharmaceutical company and the Glaucoma Association for People Affected and Families (AGAF) in collaboration and endorsed by the Spanish Glaucoma Society will publish the book ‘The 101 doubts about Glaucoma that you always wanted to know and did not dare to ask’.
  • The laboratory thus reaffirms its presence in the field of ophthalmology to benefit families, professionals and patients involved in the management of the disease.
  • Around 60 million people worldwide suffer from this eye ailment. 7.8 million of these cases are Europe-based, with a prevalence of 2.51% in the continent.
  • Salvat, an international pharmaceutical laboratory, reaffirms its presence and commitment in the field of ophthalmology to benefit families, professionals and patients involved in the treatment of glaucoma. On the occasion of the International Day of this disease, the pharmaceutical company announces the forthcoming publication of the book ‘The 101 doubts about Glaucoma that you always wanted to know and did not dare to ask’ in collaboration with the Glaucoma Association for People Affected and Relatives (AGAF) and the Spanish Glaucoma Society (SEG). Thus, both are committed to offering more effective support by identifying the specific needs of people suffering from Glaucoma.

    According to the study ‘Epidemiology of Glaucoma: The Past, Present, and Predictions for the Future’, around 60 million people worldwide are affected by primary open-angle glaucoma (POAG), with 7.8 million of those cases being Europe-based. The prevalence of the disease this continent is of 2.51%. Also, by, 2040, it is expected that more than 110 million around the world will suffer from glaucoma. It has been proven that early detection of it is essential to prevent its effects and treat it appropriately. If not, the condition may progress as a silent disease.

    ‘The 101 doubts about Glaucoma that you always wanted to know and did not dare to ask’ is part of the commitment of Salvat, AGAF and SEG to improve the quality of life of people affected by glaucoma. The book will resolve a whole series of questions of people affected by the disease that, for various reasons, they find difficult to convey to doctors. These questions have been answered thanks to the different health professionals provided by the Spanish Glaucoma Society (SEG), which has also endorsed the content of the texts. The book will have different thematic blocks: daily life, technical information about the disease, treatments and interventions, psychological aspects and improvement of disease control.

    Alberto Bueno, CEO of Laboratorios Salvat, highlights the company’s efforts to assist all those who deal with glaucoma. “As a company operating in the healthcare field, we are very clear that our work must go beyond the development of pharmaceutical products. Both professionals around the world who work on the treatment of Glaucoma and patients suffering from the disease need their necessities to be addressed, which, unfortunately, can go unnoticed. That is why we intend to continue listening to them in order to be able to work on new dissemination materials that can be useful to as many people as possible,” he explains.

    For his part, Joaquín María Carratalá, president of AGAF, stresses the help that the publication represents. “For the Glaucoma Association for Patients and Relatives, this book is the answer to many doubts that patients have raised throughout the 18 years that AGAF has been having. Addressing all these issues, giving explanations from experts and at the forefront of care for people with glaucoma, is a reference for resolving these issues. Glaucoma patients, from the moment they are diagnosed, pose problems that there is not always time to respond to in medical consultations. They also have doubts about issues that are not properly medical. For this reason, in this book we wanted to encompass all these concerns, something that for our association is a very important help when it comes to dealing with the disease. Hence our thanks to all the parties who have made this publication possible together with us.”

    Dr. Francisco J. Muñoz Negrete, president of the SEG , adds: “Due to the enormous burden of care, it is impossible to provide the patient with all the information and resolve all the doubts that arise about glaucoma and its treatment. Thanks to materials such as this manual, it will be possible to prevent those affected by the disease from resorting to incomplete, poorly verified or outright false information found on the web. Having access to science-based answers will undoubtedly improve our understanding of glaucoma. In addition, it will help the patient to improve their lifestyle habits in order to better control the disease.”